Following ‘Fosfo’

The chemical substance synthetic phosphoethanolamine (fosfoetanolamina sintética) was developed at the University of São Paulo (USP) in Brazil at the beginning of the 1990s and, until 2014, was tested on and distributed to cancer patients by members of USP’s Chemistry Institute (IQSC) in the city of...

Full description

Bibliographic Details
Main Author: Márcio Vilar
Format: Article
Language:English
Published: University of Edinburgh Library 2020-04-01
Series:Medicine Anthropology Theory
Subjects:
Online Access:http://www.medanthrotheory.org/article/view/4990
id doaj-6abc81aeb92b45f98bf109f0315fed6c
record_format Article
spelling doaj-6abc81aeb92b45f98bf109f0315fed6c2021-04-22T08:40:38ZengUniversity of Edinburgh LibraryMedicine Anthropology Theory2405-691X2020-04-017110.17157/mat.7.1.6204990Following ‘Fosfo’Márcio VilarThe chemical substance synthetic phosphoethanolamine (fosfoetanolamina sintética) was developed at the University of São Paulo (USP) in Brazil at the beginning of the 1990s and, until 2014, was tested on and distributed to cancer patients by members of USP’s Chemistry Institute (IQSC) in the city of São Carlos. That year, the production and distribution of ‘Fosfo’, as it became popularly known, was forbidden by IQSC’s director with the support of USP’s rector and the Brazilian National Sanitary Surveillance Agency (ANVISA). Shortly after this first prohibition, however, Fosfo gained popularity and became a national symbol of local scientific innovation and hope for a cancer cure. Likewise, it became an object of regulatory disputes involving multiple sectors of Brazilian society. Despite several further efforts by some scientists and patients to legitimate Fosfo as a pharmaceutical, ANVISA never authorized it. Nevertheless, at the same time as parts of Brazil’s established medical communities were becoming suspicious of Fosfo, its informal production and dissemination were increasing surreptitiously, with many Fosfo users and stakeholders questioning the legitimacy of conventional cancer therapies. In this article, I aim to understand the impact of Fosfo as a biotechnological innovation in terms of the ‘transfiguration’ of the physical and juridical persons involved in this controversy. Through the lens of transfiguration, the engagement and therapeutic-regulatory experiences of Fosfo users and stakeholders appear as deviant journeys that introduce discontinuities into established biomedicine and imply radical transformations at multiple levels, ranging from individuals to larger institutional environments.http://www.medanthrotheory.org/article/view/4990synthetic phosphoethanolamine controversyregenerative medicinetransfigurationlife assemblagesbrazil
collection DOAJ
language English
format Article
sources DOAJ
author Márcio Vilar
spellingShingle Márcio Vilar
Following ‘Fosfo’
Medicine Anthropology Theory
synthetic phosphoethanolamine controversy
regenerative medicine
transfiguration
life assemblages
brazil
author_facet Márcio Vilar
author_sort Márcio Vilar
title Following ‘Fosfo’
title_short Following ‘Fosfo’
title_full Following ‘Fosfo’
title_fullStr Following ‘Fosfo’
title_full_unstemmed Following ‘Fosfo’
title_sort following ‘fosfo’
publisher University of Edinburgh Library
series Medicine Anthropology Theory
issn 2405-691X
publishDate 2020-04-01
description The chemical substance synthetic phosphoethanolamine (fosfoetanolamina sintética) was developed at the University of São Paulo (USP) in Brazil at the beginning of the 1990s and, until 2014, was tested on and distributed to cancer patients by members of USP’s Chemistry Institute (IQSC) in the city of São Carlos. That year, the production and distribution of ‘Fosfo’, as it became popularly known, was forbidden by IQSC’s director with the support of USP’s rector and the Brazilian National Sanitary Surveillance Agency (ANVISA). Shortly after this first prohibition, however, Fosfo gained popularity and became a national symbol of local scientific innovation and hope for a cancer cure. Likewise, it became an object of regulatory disputes involving multiple sectors of Brazilian society. Despite several further efforts by some scientists and patients to legitimate Fosfo as a pharmaceutical, ANVISA never authorized it. Nevertheless, at the same time as parts of Brazil’s established medical communities were becoming suspicious of Fosfo, its informal production and dissemination were increasing surreptitiously, with many Fosfo users and stakeholders questioning the legitimacy of conventional cancer therapies. In this article, I aim to understand the impact of Fosfo as a biotechnological innovation in terms of the ‘transfiguration’ of the physical and juridical persons involved in this controversy. Through the lens of transfiguration, the engagement and therapeutic-regulatory experiences of Fosfo users and stakeholders appear as deviant journeys that introduce discontinuities into established biomedicine and imply radical transformations at multiple levels, ranging from individuals to larger institutional environments.
topic synthetic phosphoethanolamine controversy
regenerative medicine
transfiguration
life assemblages
brazil
url http://www.medanthrotheory.org/article/view/4990
work_keys_str_mv AT marciovilar followingfosfo
_version_ 1721514894074839040